Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNT142 |
Synonyms | |
Therapy Description |
BNT142 consists of an mRNA encoding a bispecific anti-Claudin 6 (CLDN6) and anti-CD3 antibody encapsulated in a lipid nanoparticle, which potentially leads to activation and proliferation of T-lymphocytes and cytotoxic T-lymphocyte mediated cell death of CLDN6-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNT142 | BNT-142|BNT 142 | BNT142 consists of an mRNA encoding a bispecific anti-Claudin 6 (CLDN6) and anti-CD3 antibody encapsulated in a lipid nanoparticle, which potentially leads to activation and proliferation of T-lymphocytes and cytotoxic T-lymphocyte mediated cell death of CLDN6-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05262530 | Phase Ib/II | BNT142 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | Recruiting | USA | GBR | ESP | 1 |